You may recall that there was a panel discussion on Mitochondrial Disease and Autism following the United Mitochondrial Disease Foundation’s (UMDF) meeting in Indianapolis. This, of course, was prompted by the news reports of the Hannah Poling case.
If you are looking for the incredibly short answer, quote mine, here it is:
To reduce the risk presented by acquired infections, the workshop panelists strongly encourage vaccinations in the hundreds of children they treat for mitochondrial disease. Among thousands of patients they had collectively seen, very few had deteriorated following vaccination, and in those few cases, it is difficult to determine that other stressors besides the vaccine did not play a role in the neurologic deterioration.
The panel discussion was held June 29th, and the report from that has just been published.
The panel was organized by people from NIH, NINDS, HHS and CDC.
Thomas R. Insel, M.D.
Director, National Institute of Mental Health, National Institutes of Health
Walter Koroshetz, M.D.
Deputy Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health
Daniel Salmon, Ph.D., M.P.H.
Vaccine Safety Specialist, U.S. Department of Health and Human Services
Ed Trevathan, M.D., M.P.H.
Director, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention
The panel included a lot of the names you would expect to hear from:
Kim M. Cecil, Ph.D.
Research Associate Professor, Cincinnati Children’s Hospital Medical Center
Bruce Cohen, M.D.
Department of Neurology, Cleveland Clinic Foundation
Stephen R. Dager, M.D.
Departments of Radiology, Psychiatry, and Bioengineering, University of Washington School of Medicine
Interim Director, University of Washington Autism Center,
Darryl DeVivo, M.D.
Sidney Carter Professor of Neurology and Pediatrics, Columbia University
Salvatore DiMauro, M.D.
Lucy G. Moses Professor of Neurology, Neurological Institute of New York, Columbia University Medical Center
Pauline Filipek, M.D.
Associate Professor of Pediatrics and Neurology, University of California, Irvine
James F. Gusella, Ph.D.
Director, Department of Genetics, Center for Human Genetic Research, Massachusetts General Hospital
Richard Haas, M.D.
Co-Director, Mitochondrial and Metabolic Disease Center, University of California, San Diego, School of Medicine
Robert K. Naviaux, M.D., Ph.D.
Co-Director, Mitochondrial and Metabolic Disease Center, University of California, San Diego, School of Medicine
Joseph Piven, M.D.
Director, Neurodevelopmental Disabilities Research Center, University of North Carolina, Chapel Hill
Roberto Tuchman, M.D.
Director, Autism Programs, Miami Children’s Hospital Dan Marino Center
Douglas Wallace, Ph.D.
Director, Center for Molecular and Mitochondrial Medicine and Genetics, University of California, Irvine
The proceedings are a summary, not a transcript of the actual event. It is a very good summary of what is known about mitochondria and mitochondrial disorders. It’s worth reading, and it is not very long. However, I’ll pull some summary information out here:
Mitochondrial genetics and biology
We all have two sets of DNA–the nuclear DNA (nDNA) that we are used to hearing about as the “blueprints” for inheritance and mitochondrial DNA (mtDNA) that are inside the mitochondria and help with the processes in the mitochondria.
Even though mitochondria are inherited from the mother, mitochondrial disease can involve both the nuclear and mitochondrial DNA, and, thus, mitochondrial diseases have multiple inheritance pathways.
You can have different mtDNA in a single cell or in different tissues–this is called heteroplasmy.
An overview of mitochondrial diseases
There are 200 mtDNA mutations and 2,000 nDNA mutations that can lead to mitochondrial disease. (The nDNA is much bigger than the mtDNA, so it isn’t surprising that more of the mutations are found on the nDNA).
The incidence of mitochondrial disease is between 1-5 in 10,000. But, the understanding is evolving.
Mitochondrial diseases present a very large spectrum. But, some generalizations can be made.
…they are typically progressive and multisystemic, most often affecting organs that have high energy demands such as the brain and nerves, skeletal and cardiac muscle, and the liver and kidneys.
There are a number of possible flags for mitochondrial disease, often when more than one area is affected at once. They noted, when the idea of autism and mitochondrial disease is discussed:
Of particular interest for this workshop, central nervous system manifestations of mitochondrial disease can include hypotonia, seizures, encephalopathy, ataxia, intellectual disabilities, global delay, and brain malformations. Sensory and peripheral nerves can also be affected, leading to deafness, blindness, or neuropathy.
Diagnosing mitochondrial disease
If you’ve already read about diagnosis of mitochondrial disease, you know it is a very complicated process.
The workshop panelists explained that diagnosis is often a lengthy process beginning with a general clinical evaluation followed by metabolic screening and imaging and finally by genetic tests and more invasive biochemical and histological analyses.
Metabolic screening, MRI, genetic testing and enzyme function through biopsy are all noted as tests, but no single test or even set of tests are definitive.
Known triggers of mitochondrial disease
If there is one section that the online autism communities are likely to zero in on, it’s this.
Mitochondrial diseases can go undetected for many years, and many cases display an episodic course with relatively stable periods punctuated by abrupt degeneration that may coincide with an infection or other stress to mitochondrial function.
If you’ve been thinking about this a lot, you’ve probably asked yourself how the mitochondria react during a fever. Fevers are an increase in temperature, which, naturally, takes an increased energy output.
Of possible importance, mitochondria are the major generators of body heat and are therefore extremely active during fever. It is not known whether fever or other aspects of the inflammatory or immune response to a virus or bacteria trigger deterioration after infection
The phrase that probably will be the one take-away for most people in the autism community who have been following the mitochondrial issue:
To reduce the risk presented by acquired infections, the workshop panelists strongly encourage vaccinations in the hundreds of children they treat for mitochondrial disease. Among thousands of patients they had collectively seen, very few had deteriorated following vaccination, and in those few cases, it is difficult to determine that other stressors besides the vaccine did not play a role in the neurologic deterioration.
From what I’ve heard, they were very, very strong in their recommendation for vaccination to protect against infectious disease in this very vulnerable population.
Other triggers include dehyration, reduced caloric intake or, in some cases, exercise.
Environmental causes of mitochondrial impairment: AZT, valproate, statins, chemicals like MPTP and the pesticide rotenone, fungal toxins, and even cigarette smoke and alcohol.
Mitochondrial diseases and autism: clinical parallels and evidence for a relationship
Both Autism and Mitochondrial Disease are broad spectrums. The subtypes for autism are less well defined, making it hard to make good comparison. It is difficult to pull only a couple phrases out of this section, but I will pick two:
Workshop panelists who treat children with mitochondrial disease noted that some of these children have autistic features, and some children eventually found to have mitochondrial disease are initially diagnosed with an ASD. In addition, siblings of children with maternally inherited mitochondrial disorders sometimes present with autism. Presumably, they have inherited the same mitochondrial mutation from their mother, but the mutation may be difficult to find. Workshop panelists who mainly see individuals with a primary diagnosis of autism found parallels with clinical observations in mitochondrial disease such as developmental regression, seizures, and gastrointestinal complications
and,
Additional parallels between ASDs and mitochondrial disease noted by the workshop panelists were in family histories and patterns of inheritance. These included possible maternal inheritance in some ASDs, a similar higher prevalence in males for both ASDs and some mitochondrial diseases, and a high frequency of psychiatric conditions such as depression, delusions and attention deficit disorder in families with mitochondrial disease, including in relatives who seem otherwise unaffected.
Advancing research on the relationship between mitochondrial disease and autism: needs, priorities and emerging tools
This section notes two types of studies which they suggest should be done: a targeted and an unbiased approach.
By targeted they mean a study that
…would involve a thorough investigation of a relatively small ASD population selected for characteristics that indicate a greater likelihood of mitochondrial involvement. Such a strategy might involve more in-depth or invasive testing, including, for example, muscle biopsy and brain imaging with MR spectroscopy.
On the other hand, the unbiased approach:
… would instead survey a larger, more diverse population and could inform questions about the extent to which mitochondrial disease contributes to ASDs more broadly.
From my perspective, both sound like good avenues for research–neither better or more important than the other.
If you are following this subject, I would again urge you to read the entire summary. It isn’t very long. It is unfortunate that people (myself included) will pull bits and pieces out.
Recent Comments